The Clinical Relevance of Rising CA-125 Levels Within the Normal Range in Patients With Uterine Papillary Serous Cancer
Authors:
- 1 April 2013
- journal article
- research article
- Published by Springer Nature in Reproductive Sciences
- Vol. 20 (4) , 449-455
Abstract
The utility of cancer antigen 125 (CA-125) levels as an adjunct method of monitoring patients with uterine papillary serous carcinoma (UPSC) or endometrial serous carcinoma after surgery and adjuvant treatment has been reported. Our goal was to determine the significance of rising CA-125 levels within the normal range in these patients in the posttreatment surveillance setting. All patients with UPSC who underwent surgical staging and had preoperative CA-125 measurement from 1999 to 2008 were included in this analysis. Information was extracted from records to assess the changes in CA-125 values with clinical and/or radiographic detection of recurrence. Of the 56 evaluable patients, 23 (41%) recurred. Of the 23 patients that recurred, 11 had serial CA-125 levels measured in remission. Elevated CA-125 levels at diagnosis were significantly associated with disease recurrence and advanced stage (P = .01, P = .001, respectively). The rise in CA-125 by 10 U/mL in the normal range and ≥15 U/mL were associated with disease recurrence (P < .001, P < .001, respectively). In multivariate analysis, only CA-125 level ≥15 U/mL was significantly associated with worse progression-free survival. In this small cohort of patients with recurrent UPSC after remission, surveillance of CA-125 levels may have a role in disease surveillance and management.Keywords
This publication has 20 references indexed in Scilit:
- Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous CarcinomaInternational Journal of Gynecological Cancer, 2011
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2010
- Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review☆Gynecologic Oncology, 2009
- Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levelsAnnals of Oncology, 2008
- Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinomaGynecologic Oncology, 2008
- Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancerAnnals of Oncology, 2007
- An Early Signal of CA-125 Progression for Ovarian Cancer Patients Receiving Maintenance Treatment After Complete Clinical Response to Primary TherapyJournal of Clinical Oncology, 2007
- Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian CancerJournal of Clinical Oncology, 2006
- Risk of Epithelial Ovarian Cancer Recurrence in Patients With Rising Serum CA-125 Levels Within the Normal RangeJournal of Clinical Oncology, 2005
- Value of Preoperative CA 125 Level in the Management of Uterine Cancer and Prediction of Clinical OutcomeObstetrics & Gynecology, 1997